Prognostic Evaluation Using Nutrition-Inflammation Biomarkers from Routine Blood Tests in Metastatic Breast Cancer: A Boruta Algorithm-Optimized Feature Selection Study - Report - MDSpire

Prognostic Evaluation Using Nutrition-Inflammation Biomarkers from Routine Blood Tests in Metastatic Breast Cancer: A Boruta Algorithm-Optimized Feature Selection Study

  • By

  • Nong, Wen-xiong

  • Huang, Sheng-kai

  • Zhang, Wenhai

  • Tan, Yang

  • Wu, Zhi-dong

  • Liang, Wan-wang

  • Wu, Rui-zheng

  • May 13, 2026

  • 0 min

Share

Clinical Report: Prognostic Value of Nutrition and Inflammation Biomarkers in MBC

Overview

This study evaluates the prognostic significance of nutrition and inflammation biomarkers derived from standard blood tests in patients with metastatic breast cancer. Key findings indicate that MLR, SIRI, ALI, AGR, and PA are independent predictors of overall survival, with specific thresholds associated with increased mortality risk.

Background

Understanding the prognostic factors in metastatic breast cancer is crucial for optimizing patient management and improving outcomes. Nutrition and inflammation indices derived from routine blood tests may provide valuable insights into patient prognosis. This study aims to identify the most clinically applicable biomarkers to guide treatment decisions.

Data Highlights

{'format': 'Ensure the table is properly formatted for readability.'}

Key Findings

{'add_methodology': 'Include a brief description of the methods used to derive the findings.'}

Clinical Implications

{'add_limitations': 'Mention any limitations or considerations when applying these biomarkers.'}

Conclusion

{'add_research': 'Suggest areas for future research to strengthen the conclusions.'}

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis
  2. The ASCO Post, 2026 -- Inflammatory Breast Cancer: Blood-Based Biomarkers Identified
  3. Evaluating the Prognostic Significance of Standard Blood Biomarkers for Three-Year Survival in Patients with Resectable Colorectal Cancer: A Clinical Nomogram Approach
  4. The ASCO Post, 2024 -- New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
  5. Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline - PubMed
  6. Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline - PubMed
  7. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer | New England Journal of Medicine
  8. Prognostic role of the systemic immune-inflammation index and pan-immune inflammation value for outcomes of breast cancer: a systematic review and meta-analysis - PubMed

Original Source(s)

Prognostic Evaluation Using Nutrition-Inflammation Biomarkers from Routine Blood Tests in Metastatic Breast Cancer: A Boruta Algorithm-Optimized Feature Selection Study

  • by Nong, Wen-xiong , Huang, Sheng-kai , Zhang, Wenhai , Tan, Yang , Wu, Zhi-dong , Liang, Wan-wang , Wu, Rui-zheng

  • May 13, 2026

Related Content

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

High-grade astrocytoma with piloid features: a case report of comprehensive management